http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_36b5edaa83e5476e2b872a3fc6ae82fb
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Kraeber-Bodéré |
| name | Françoise Kraeber-Bodéré |
| given-name | Françoise |
| organization-name | Nuclear Medicine Department, René Gauducheau Cancer Center, 44805 Saint Herblain, France. Nuclear Medicine Department, René Gauducheau Cancer Center, Nantes, France. francoise.bodere@chu-nantes.fr University Hospital, Nantes, France Centre de Recherche en Cancérologie Nantes-Angers, INSERM, Université de Nantes, Nantes, France Authors' Affiliations: 1Medical Oncology Service, Hospital del Mar; 2Cancer Research Program, IMIM; 3Autonomous University of Barcelona, Barcelona; 4Department of Pathology, IIS-Fundación Jiménez Díaz, Madrid, Spain; 5The Cancer Therapeutics Unit/The Drug Development Unit, The Institute of Cancer Research/Royal Marsden Hospital, London, United Kingdom; 6SITEP, Department of Medicine, Institut Gustave Roussy, Villejuif, and University Paris-Sud, Paris; 7Department of Nuclear Medicine/Center for PET/CT, University Hospital and ICO, René Gauducheau Cancer Center, INSERM Unit 892, CRCNA Nantes, France; 8F. Hoffmann-La Roche Ltd., Basel, Switzerland; 9F. Hoffmann-La Roche Ltd., Nutley, New Jersey; and 10.Roche Diagnostics GmbH, Penzberg, Germany From the Service des Maladies du Sang, Centre Hospitalier Regional, L'Universitaire de Lille; Institut de Biologie, L'Institut National de la Santé et de la Recherche Médicale Unit 892, Centre de Recherche en Cancérologie Nantes-Angers; Centre Hospitalier Universitaire, Nantes; Centre René Gauducheau, Institut Régional du Cancer Nantes-Atlantique, Nantes-Saint-Herblain, France; Immunomedics, Morris Plains; Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ; Georg... Nuclear Medicine Department, Nantes University Hospital, CRCINA INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France Institut National de la Santé et de la Recherche Médicale Research Unit 463, CEA L. R. C. 18V, Regional Cancer Center, 44093 Nantes, France. Nuclear Medicine Unit, University Hospital, Nantes, France;; INSERM U892, CRCNA, Nantes, France;; Nuclear Medicine Unit, ICO-Gauducheau, Nantes-Saint-Herblain, France 13Nuclear Medicine Department, Hôtel-Dieu University Hospital, Nantes, France. Nuclear Medicine Unit, ICO Cancer Center, Saint Herblain, France; Nantes-Angers Cancer Research Center, INSERM U892, CNRS UMR 6299, University of Nantes, Nantes, France Department of Nuclear Medicine, University Hospital, 44093 Nantes, France; Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Nantes, France; Department of Nuclear Medicine, Institut de Cancérologie de l’Ouest (ICO) – Site Gauducheau, Saint Herblain, France CRCNA, INSERM U892, CNRS UMR 7299, Université de Nantes, IRS-UN, Nantes, France Authors' Affiliations: 1The Netherlands Cancer Institute, Amsterdam; 2Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; 3Oxford NIHR Biomedical Research Centre, Department of Oncology, University of Oxford, Churchill Hospital, Oxford, United Kingdom; 4Medical Oncology Department, Institut Curie, Paris; 5Department of Nuclear Medicine/Center for PET/CT, University Hospital and ICO, René Gauducheau Cancer Center, INSERM Unit 892, Nantes, France; 6Department of Medicine (Cancer Research), West German Cancer Center, University Hospital Essen, Essen; 7Roche Diagnostics GmbH, Penzberg, Germany; 8F.Hoffmann-La Roche Ltd., Basel, Switzerland; and 9F.Hoffmann-La Roche Ltd., Nutley, New Jersey Nantes University, CHU Nantes, CNRS, Inserm, CRCINA, Nantes, France Nuclear Medicine and Haematology, CHU Nantes, Nantes, France; Nuclear Medicine Department, University Hospital, Nantes, France; Nantes-Angers Cancer Research Center CRCINA, University of Nantes, INSERM UMR1232, CNRS-ERL6001, Nantes, France; Nuclear Medicine Department, ICO-René Gauducheau Cancer Center, Saint-Herblain, France 1Nantes-Angers Cancer Research Center (CRCINA), University of Nantes, Inserm UMR1232, Nantes, France.; 2Department of Nuclear Medicine, CHU de Nantes, Nantes, France.; 12Department of Nuclear Medicine, ICO-René Gauducheau, Saint-Herblain, France. Nuclear Medicine Unit, ICO Cancer Center Gauducheau, Saint Herblain, France; Nantes-Angers Cancer Research Center, INSERM U892, CNRS UMR 6299, University of Nantes, Nantes, France; Nuclear Medicine Unit, University Hospital, Nantes, France CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France; Nuclear Medicine Department, ICO René Gauducheau Cancer Center, Saint Herblain, France; Nuclear Medicine Department, University Hospital, Nantes, France |
Incoming Links
Total number of triples: 147.